In this segment on early relapse multiple myeloma, Luciano Costa expands the discussion on safety by focusing on practical strategies to mitigate the characteristic toxicities associated with BCMA-directed bispecific antibodies. Inviting input from Carol Ann Huff, he highlights that adverse events such as cytokine release syndrome and infections remain a central topic of clinical discussion. Dr. Huff outlines a proactive approach to toxicity management, emphasizing the importance of step-up dosing protocols, early recognition of symptoms, and timely intervention to minimize severity. She also discusses infection risk mitigation, including monitoring, supportive care strategies, and patient education to ensure prompt reporting of symptoms. The panel underscores that experience and familiarity with these agents have improved clinicians’ ability to manage these toxicities effectively. Overall, this segment reinforces that while safety considerations are important in multiple myeloma, structured mitigation strategies can support the safe and effective use of bispecific antibody therapies.
